Japan’s Sosei Group has completed a transition to a commercial-stage pharmaceutical company after buying rights to an already-marketed drug and a pipeline of experimental
Swiss biotech Idorsia has suffered a setback in its bid to develop clazosentan for a form of stroke in the west, despite winning approval of the drug in Japan last year.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh